...
zlab-img

Zai Lab Ltd, Common Stock

ZLAB

NMQ

$26.54

-$0.18

(-0.67%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$2.91B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
243.86K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.04
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$13.48 L
$36.6 H
$26.54

About Zai Lab Ltd, Common Stock

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZLABSectorS&P500
1-Week Return1.38%-0.94%-2.6%
1-Month Return-5.52%-5.08%-1.08%
3-Month Return28.09%-10.62%3.45%
6-Month Return41.55%-6.18%8.57%
1-Year Return2.79%1.98%24.3%
3-Year Return-59.69%-0.93%25.58%
5-Year Return-32.3%33.84%84.07%
10-Year Return-4.98%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue12.98M48.96M144.31M215.04M266.72M[{"date":"2019-12-31","value":4.87,"profit":true},{"date":"2020-12-31","value":18.36,"profit":true},{"date":"2021-12-31","value":54.11,"profit":true},{"date":"2022-12-31","value":80.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue3.75M16.74M52.24M74.02M95.82M[{"date":"2019-12-31","value":3.91,"profit":true},{"date":"2020-12-31","value":17.47,"profit":true},{"date":"2021-12-31","value":54.52,"profit":true},{"date":"2022-12-31","value":77.25,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit9.24M32.22M92.07M141.02M170.90M[{"date":"2019-12-31","value":5.4,"profit":true},{"date":"2020-12-31","value":18.85,"profit":true},{"date":"2021-12-31","value":53.87,"profit":true},{"date":"2022-12-31","value":82.52,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin71.13%65.82%63.80%65.58%64.08%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.53,"profit":true},{"date":"2021-12-31","value":89.7,"profit":true},{"date":"2022-12-31","value":92.2,"profit":true},{"date":"2023-12-31","value":90.08,"profit":true}]
Operating Expenses212.43M334.02M792.14M545.38M547.48M[{"date":"2019-12-31","value":26.82,"profit":true},{"date":"2020-12-31","value":42.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":68.85,"profit":true},{"date":"2023-12-31","value":69.11,"profit":true}]
Operating Income(203.20M)(301.80M)(700.06M)(404.36M)(366.57M)[{"date":"2019-12-31","value":-20319593900,"profit":false},{"date":"2020-12-31","value":-30180100000,"profit":false},{"date":"2021-12-31","value":-70006400000,"profit":false},{"date":"2022-12-31","value":-40435700000,"profit":false},{"date":"2023-12-31","value":-36657300000,"profit":false}]
Total Non-Operating Income/Expense16.82M38.95M(1.16M)(24.13M)70.79M[{"date":"2019-12-31","value":23.75,"profit":true},{"date":"2020-12-31","value":55.03,"profit":true},{"date":"2021-12-31","value":-1.64,"profit":false},{"date":"2022-12-31","value":-34.08,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(194.32M)(267.79M)(703.41M)(443.06M)(334.62M)[{"date":"2019-12-31","value":-19431892400,"profit":false},{"date":"2020-12-31","value":-26778600000,"profit":false},{"date":"2021-12-31","value":-70341400000,"profit":false},{"date":"2022-12-31","value":-44306500000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false}]
Income Taxes(10.95M)30.38M(10.97M)38.93M38.93M[{"date":"2019-12-31","value":-28.14,"profit":false},{"date":"2020-12-31","value":78.03,"profit":true},{"date":"2021-12-31","value":-28.18,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(183.37M)(298.16M)(692.44M)(481.99M)(373.55M)[{"date":"2019-12-31","value":-18336589400,"profit":false},{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-37354900000,"profit":false}]
Income From Continuous Operations(195.07M)(268.90M)(704.47M)(443.29M)(300.96M)[{"date":"2019-12-31","value":-19507100000,"profit":false},{"date":"2020-12-31","value":-26890500000,"profit":false},{"date":"2021-12-31","value":-70447100000,"profit":false},{"date":"2022-12-31","value":-44328600000,"profit":false},{"date":"2023-12-31","value":-30096000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(183.37M)(298.16M)(692.44M)(481.99M)(334.62M)[{"date":"2019-12-31","value":-18336589400,"profit":false},{"date":"2020-12-31","value":-29816200000,"profit":false},{"date":"2021-12-31","value":-69244400000,"profit":false},{"date":"2022-12-31","value":-48199400000,"profit":false},{"date":"2023-12-31","value":-33462000000,"profit":false}]
EPS (Diluted)(2.62)(2.78)(7.58)(4.67)(3.47)[{"date":"2019-12-31","value":-261.87,"profit":false},{"date":"2020-12-31","value":-277.62,"profit":false},{"date":"2021-12-31","value":-758,"profit":false},{"date":"2022-12-31","value":-467,"profit":false},{"date":"2023-12-31","value":-347,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZLAB
Cash Ratio 2.15
Current Ratio 3.01
Quick Ratio 2.87

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZLAB
ROA (LTM) -20.83%
ROE (LTM) -34.98%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZLAB
Debt Ratio Lower is generally better. Negative is bad. 0.32
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.68

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZLAB
Trailing PE NM
Forward PE NM
P/S (TTM) 8.13
P/B 4.36
Price/FCF NM
EV/R 6.74
EV/Ebitda NM

FAQs

What is Zai Lab Ltd share price today?

Zai Lab Ltd (ZLAB) share price today is $26.54

Can Indians buy Zai Lab Ltd shares?

Yes, Indians can buy shares of Zai Lab Ltd (ZLAB) on Vested. To buy Zai Lab Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZLAB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Zai Lab Ltd be purchased?

Yes, you can purchase fractional shares of Zai Lab Ltd (ZLAB) via the Vested app. You can start investing in Zai Lab Ltd (ZLAB) with a minimum investment of $1.

How to invest in Zai Lab Ltd shares from India?

You can invest in shares of Zai Lab Ltd (ZLAB) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZLAB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Zai Lab Ltd shares
What is Zai Lab Ltd 52-week high and low stock price?

The 52-week high price of Zai Lab Ltd (ZLAB) is $36.6. The 52-week low price of Zai Lab Ltd (ZLAB) is $13.48.

What is Zai Lab Ltd price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Zai Lab Ltd (ZLAB) is

What is Zai Lab Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Zai Lab Ltd (ZLAB) is 4.36

What is Zai Lab Ltd dividend yield?

The dividend yield of Zai Lab Ltd (ZLAB) is 0.00%

What is the Market Cap of Zai Lab Ltd?

The market capitalization of Zai Lab Ltd (ZLAB) is $2.91B

What is Zai Lab Ltd’s stock symbol?

The stock symbol (or ticker) of Zai Lab Ltd is ZLAB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top